📊 SNDX Key Takeaways
Is Syndax Pharmaceuticals Inc (SNDX) a Good Investment?
Syndax demonstrates exceptional 627.8% YoY revenue growth indicating strong product-market fit and successful commercialization. However, the company remains deeply unprofitable with -52.7% operating margins and burns $50.3M annually, providing only ~2.6 years of runway at current burn rates. Fundamental viability depends critically on achieving profitability before cash reserves are exhausted.
Why Buy Syndax Pharmaceuticals Inc Stock? SNDX Key Strengths
- Exceptional revenue growth of 627.8% YoY demonstrates validated product-market fit and successful commercialization
- Strong cash position of $130.9M with excellent liquidity ratios (5.47x current, 5.06x quick) provides substantial operating runway
- Conservative debt structure with Debt/Equity ratio of 0.48x and modest long-term debt of $20.0M
SNDX Stock Risks: Syndax Pharmaceuticals Inc Investment Risks
- Severe operational cash burn of -$50.3M annually with only ~2.6 years of runway before cash depletion at current burn rates
- Deeply unprofitable operations with -52.7% operating margin and -65.8% net margin despite massive revenue growth, indicating high unit costs or operating inefficiency
- No visible path to profitability; company must demonstrate unit economics improvement and margin expansion to avoid cash crisis before achieving sustainable operations
Key Metrics to Watch
- Operating margin trajectory and gross margin expansion with revenue scaling
- Operating cash flow and cash burn rate trends relative to revenue growth
- Timeline to cash flow breakeven and profitability achievement
Syndax Pharmaceuticals Inc (SNDX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.47x current ratio provides a solid financial cushion.
SNDX Profit Margin, ROE & Profitability Analysis
SNDX vs Healthcare Sector: How Syndax Pharmaceuticals Inc Compares
How Syndax Pharmaceuticals Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Syndax Pharmaceuticals Inc Stock Overvalued? SNDX Valuation Analysis 2026
Based on fundamental analysis, Syndax Pharmaceuticals Inc shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Syndax Pharmaceuticals Inc Balance Sheet: SNDX Debt, Cash & Liquidity
SNDX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Syndax Pharmaceuticals Inc's revenue has grown significantly by 23% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.98 indicates the company is currently unprofitable.
SNDX Revenue Growth, EPS Growth & YoY Performance
SNDX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $20.0M | -$42.7M | $-0.48 |
| Q3 2025 | $12.5M | -$60.7M | $-0.70 |
| Q2 2025 | $3.5M | -$68.1M | $-0.80 |
| Q1 2025 | N/A | -$72.4M | $-0.85 |
| Q3 2024 | N/A | -$41.1M | $-0.73 |
| Q2 2024 | N/A | -$41.1M | $-0.64 |
| Q3 2022 | $12.4M | -$20.6M | $-0.40 |
| Q2 2022 | $379.0K | -$22.9M | $-0.44 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Syndax Pharmaceuticals Inc Dividends, Buybacks & Capital Allocation
SNDX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Syndax Pharmaceuticals Inc (CIK: 0001395937)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SNDX
What is the AI rating for SNDX?
Syndax Pharmaceuticals Inc (SNDX) has an AI rating of HOLD with 48% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SNDX's key strengths?
Claude: Exceptional revenue growth of 627.8% YoY demonstrates validated product-market fit and successful commercialization. Strong cash position of $130.9M with excellent liquidity ratios (5.47x current, 5.06x quick) provides substantial operating runway.
What are the risks of investing in SNDX?
Claude: Severe operational cash burn of -$50.3M annually with only ~2.6 years of runway before cash depletion at current burn rates. Deeply unprofitable operations with -52.7% operating margin and -65.8% net margin despite massive revenue growth, indicating high unit costs or operating inefficiency.
What is SNDX's revenue and growth?
Syndax Pharmaceuticals Inc reported revenue of $64.9M.
Does SNDX pay dividends?
Syndax Pharmaceuticals Inc does not currently pay dividends.
Where can I find SNDX SEC filings?
Official SEC filings for Syndax Pharmaceuticals Inc (CIK: 0001395937) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SNDX's EPS?
Syndax Pharmaceuticals Inc has a diluted EPS of $-0.48.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SNDX a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Syndax Pharmaceuticals Inc has a HOLD rating with 48% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SNDX stock overvalued or undervalued?
Valuation metrics for SNDX: ROE of -102.5% (sector avg: 15%), net margin of -65.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SNDX stock in 2026?
Our dual AI analysis gives Syndax Pharmaceuticals Inc a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SNDX's free cash flow?
Syndax Pharmaceuticals Inc's operating cash flow is $-50.3M, with capital expenditures of $187.0K. FCF margin is -77.9%.
How does SNDX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -65.8% (avg: 12%), ROE -102.5% (avg: 15%), current ratio 5.47 (avg: 2).